Fast Money Now – the trades you need while the market is open.
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.
The health-care sector has been getting healthier, according to Schwab's Paul Alan Davis.
Health care stocks have been the stealth performers, and they will likely continue to outperform because of steady earnings, a favorable macro environment and cheap valuations, says Merrill Lynch's Brian Belski.
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.
Ed Sheidlower is avoiding financials. But the Bryce Capital Management portfolio manager sees other sectors -- and stocks -- as good investments.
To give investors an edge, CNBC asked the experts for their best stock picks now.
Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now.
At a time of market uncertainty, what can an investor count on? Knee replacements, for one thing. Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.
By anyone's reckoning, it was a rough week. Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged. But all week, even through the worst of the market's sell-offs, CNBC guests offered
FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."
The second half of 2008 looks mighty encouraging to Al Meyers. "It's all going to depend upon earnings," he told CNBC. "It's going to set the tone for the second half. There are some very good values out there right now."
Cramer makes the call on viewers' favorite stocks.
Following are the day’s biggest winners and losers. Find out why shares of Time Warner and Borders popped while AIG and Boeing dropped.
Following are the day’s biggest winners and losers. Find out why shares of Humana and Medtronic popped while DryShips and J.C. Penney dropped.
Stocks finished near session lows as oil prices soared and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
Stocks tumbled Tuesday as oil prices blew past $129 a barrel and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.
Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?